Utilization study of filgrastim (Neutromax®) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients

To describe utilization of a biosimilar product containing filgrastim (Neutromax®), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 μg/day) and for the recovery of neutropenia after transplantation (100 μg/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 × 106 CD34+ cells/kg was infused; 100 neutrophils/mm3 required 5-day treatment; 500 neutrophils/mm3, 6 days and 1000 neutrophils/mm3, 7 days. Neutromax® effect in SCT is similar to reports with other brands. No difference was found between formulations.